Insiders who reported open-market trades in the last 12 months at the companies Robert J. Bitterman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Ronald Todd Plott - $27K in PHIO purchases and sales in the last 12 months
Robert J. Bitterman is a corporate insider, tracked as Chairman, Pres. & CEO, Director of Phio Pharmaceuticals Corp. (PHIO). InsiderAlpha holds 14 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Robert J. Bitterman submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Robert J. Bitterman been buying or selling stock?
Recorded transactions: 11 open-market purchases ($61K) and 0 open-market sales across all tracked filings.
Robert J. Bitterman is Chairman, Pres. & CEO, Director of Phio Pharmaceuticals Corp. (PHIO). 14 SEC Form 4 filings on record going back to 2025, most recently on 29 September 2026. Most recent open-market trade: bought $2K of PHIO on 23 September 2026. Lifetime open-market purchases: $61K.
Recent transactions
16
The latest 16 SEC Form 4 transactions reported by Robert J. Bitterman.
InsiderAlpha's records for Robert J. Bitterman go back to 2025: 14 primary Form 4 filings, an average of 7.0 per year. The typical open-market purchase is $6K (11 buys totaling $61K). The largest single buy on record is $11K of PHIO in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
